NX Development Corp | WebDisclosure

Basculer en Français

8396	Companies
122097	Keywords
60577	Articles
65553	Press releases

Home
Companies
NX Development Corp

BRIEF

published on 06/21/2024 at 15:05, 6 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)

Gleolan NX Development Corp. OVA-302 Study FDA Orphan Designation
BRIEF

published on 06/21/2024 at 15:05, 6 months ago

NX Development Corp. recrute le premier patient dans l'étude OVA-302 après la désignation d'orphelin par la FDA pour Gleolan(R)

Gleolan NX Développement Corp. Étude OVA-302 Désignation Orpheline De La FDA
PRESS RELEASE

published on 06/21/2024 at 15:00, 6 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)
NX Development Corp. enrolls first patient in OVA-302 study for cancer management using Gleolan following FDA's Orphan Designation. CEO DeSena and Chairman Kosciessa express excitement for future programs

Gleolan NX Development Corp. OVA-302 Study Cancer Management Flourescence-guided Surgery
BRIEF

published on 03/05/2024 at 23:05, 9 months 15 days ago

NX Development Corp. Awarded Orphan-Drug Designation for Gleolan in Ovarian Cancer Treatment

FDA NX Development Corp Orphan-Drug Designation Gleolan Ovarian Cancer
BRIEF

published on 03/05/2024 at 23:05, 9 months 15 days ago

NX Development Corp. reçoit la désignation de médicament orphelin pour Gleolan dans le traitement du cancer de l'ovaire

FDA Gleolan NX Development Corp. Désignation De Médicament Orphelin Cancer Des Ovaires
PRESS RELEASE

published on 03/05/2024 at 23:00, 9 months 15 days ago

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers
NX Development Corp. has achieved orphan-drug status from the FDA for Gleolan, aiding in the visualization of ovarian tumors during surgery. The milestone highlights innovation in cancer care and surgery

FDA Cancer Care Gleolan NX Development Corp. Orphan-drug Status

Accesswire

Published on 12/21/2024 at 01:30, 17 hours 57 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 57 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 22 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 19 hours 27 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 57 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 12/21/2024 at 00:51, 18 hours 35 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 41 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 1 day ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

ARYZTA AG Announces New Board Technology Committee

Les Echos

Published on 12/21/2024 at 12:17, 7 hours 9 minutes ago

AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 7 hours 9 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024

View all LES ECHOS COMFI WIRE